CD20 B-Cell Non-Hodgkin Lymphoma clinical trials
6 active B-Cell Non-Hodgkin Lymphoma trials that test for CD20 in their eligibility criteria. Describe your situation to see which ones look like a fit.
- Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
- Phase I/II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
- A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
- CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
- A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
- Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
← All B-Cell Non-Hodgkin Lymphoma trials
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.